

INFORMATION DISCLOSURE STATEMENT


FORM PTO 1449 (modified)

ATTY DOCKET NO.
2007_0363SERIAL NO.
10/517,847U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: October 16, 2008

APPLICANT
Keiji KAMIYAMAFILING DATE
June 24, 2005

OCT 16 2008



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	BA						
	BB						
	BC						

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	CA	Japanese Office Action (with English translation) Notice of Reasons for Refusal in corresponding Japan Application mailed on July 15, 2008.
	CB	Hitoshi Sezaki, Drug Delivery System, Kabushiki Kaisha Nankodo, April 15, 1986, first edition pp. 49-56
	CC	Jackie A.Highfield et al., J. Chem. Soc., Perkin Trans 1, 1999, pp. 2343-2351
	CD	Joel Oiry et al., Bioorganic & Medicinal Chemistry Letters, 2001, 11(9), pp. 1189-1191.

EXAMINER

/Taofiq Solola/

DATE CONSIDERED

03/05/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.S./